LOGO
LOGO

Debt-Free Balance Sheet, MACI Momentum, And Burn Care Portfolio Put Vericel On Investors' Radar

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
vericelcorp 14012026 lt

Is Vericel Corp. (VCEL) setting the stage for another year of growth? With profitability for the second straight year, no debt, and strategic investments fueling future expansion, the company's preliminary 2025 results highlight rising revenue, expanding MACI utilization, and plans for new manufacturing capacity as it heads into 2026.

Vericel, a company specializing in sports medicine and burn care treatments, reported preliminary total net revenue of about $276 million for 2025, with MACI contributing $239.5 million and burn care products generating $36.5 million.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.